2 results
Approved WMOCompleted
To determine the conversion rate of PR to CR (i.e. PET negativity) after a single dose of 90Y-ibritumomab tiuxetan (a dose of 14.8 MBq/kg or 0.4 mCi/kg, max 1184 MBq or 32mCi) in patients with grade 1-3a, stage II, III or IV follicular lymphoma with…
Approved WMOCompleted
To demonstrate superiority of the NEURO TRONIC SC-KAFO in stance control securing while walking under challenging conditions compared to the E-MAG Active SC-KAFO; and to demonstrate superiority of the NEURO TRONIC SC-KAFO on walking energy cost,…